Advertisement

Topics

Safety Study of F2695 SR in Major Depressive Disorder

2010-07-15 17:00:00 | BioPortfolio

Summary

The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.

Study Design

Control: Active Control, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Major Depressive Disorder

Intervention

F2695 SR

Location

Forest Investigative Site 55
Dothan
Alabama
United States
36305

Status

Enrolling by invitation

Source

Forest Laboratories

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [1444 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of F2695 SR in Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety, and tolerability of F2695 SR fixed doses versus placebo in the treatment of outpatients with major depressive disorder.

Safety and Efficacy of F2695 SR in Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety, and tolerability of F2695 SR versus placebo in the treatment of outpatients with major depressive disorder

Safety and Efficacy of F2695 SR in Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety, and tolerability of F2695 SR versus placebo in the treatment of outpatients with major depressive disorder.

Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

The purpose of this study is to evaluate the safety and efficacy of F2695 sustained release (SR) relative to placebo in the prevention of depression relapse in patients with major depressi...

Study Of 323U66 SR In Major Depressive Disorder

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.

PubMed Articles [9699 Associated PubMed Articles listed on BioPortfolio]

TNFAIP3 mRNA Level Is Associated with Psychological Anxiety in Major Depressive Disorder.

Major depressive disorder has been shown to be associated with inflammation and the dysregulation of innate immune responses. Previously, we showed an inverse correlation between the severity of depre...

Exploratory study of imagery rescripting without focusing on early traumatic memories for major depressive disorder.

Mental imagery has a more powerful impact on our emotions than thinking in words about the same material. Treating intrusive images with imagery rescripting (IR) has been reported for various disorder...

Co-morbid depressive disorder is associated with better neurocognitive performance in first episode schizophrenia spectrum.

Both major depressive disorder (MDD) and first episode schizophrenia spectrum (FES) are associated with significant neurocognitive deficits. However, it remains unclear whether the neurocognitive defi...

Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.

Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo-controlled treatment trials. This study reports a ...

Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with Major Depressive Disorder, Bipolar Disorder I, and Major Depressive with Alcohol Use Disorders.

Dorsolateral prefrontal cortex (DLPFC) is critically involved in mood and alcohol use disorders.

Medical and Biotech [MESH] Definitions

A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).

An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

More From BioPortfolio on "Safety Study of F2695 SR in Major Depressive Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial